Gilead Sciences entered into licensing agreement with Japan Tobacco (JT) to develop and commercialize Japan Tobacco’s HIV integrase inhibitor (JTK-303) in all countries of the world, excluding Japan. JTK-303 is in phase 1 clinical trials and Gilead intends to initiate phase 1/2 trial. The deal could be worth up to US$105 M to Japan Tobacco if specific milestones and sales targets are met. The analyst opinion article states that product acquisitions and progress its own research programs into clinical development.